Financial Contrast: FibroGen (NASDAQ:FGEN) vs. Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics (NASDAQ:UNCY) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Unicycive Therapeutics and FibroGen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	109.07	-$30.54 million	($0.97)	-0.74
FibroGen	$147.75 million	0.23	-$284.23 million	($1.23)	-0.27

Unicycive Therapeutics has higher earnings, but lower revenue than FibroGen. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 72.7% of FibroGen shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by insiders. Comparatively, 2.0% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Unicycive Therapeutics and FibroGen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	0	0	4	1	3.20
FibroGen	0	1	0	0	2.00

Unicycive Therapeutics presently has a consensus target price of $5.13, indicating a potential upside of 617.28%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than FibroGen.

Risk & Volatility

Unicycive Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Unicycive Therapeutics and FibroGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	N/A	-29.88%
FibroGen	-67.66%	N/A	-36.17%

Summary

Unicycive Therapeutics beats FibroGen on 11 of the 14 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.